What is White Biotechnology's Remuneration Committee?

The Remuneration Committee is a subcommittee of the Board of Directors responsible for deliberating and deciding on matters related to executive compensation. At White Biotechnology, it is primarily composed of independent directors.

Why are the members of the Remuneration Committee changing?

The terms of the committee members have expired, leading the Board of Directors to decide on re-appointments and new appointments. This is a regular procedure within the company's governance framework.

Who is the new member, Cheng Chien-Hsin?

Mr. Cheng Chien-Hsin serves as the Director and General Manager of San Fu Biomedical Co., Ltd. He is expected to bring new perspectives and expertise.

Will this personnel change affect the company's performance?

A direct impact is currently unclear, but a stable compensation system and proper governance can contribute to long-term corporate value enhancement.

What are White Biotechnology's future business plans?

This announcement concerns the members of the Remuneration Committee; specific business development details are pending further disclosure. The company is advancing research and development in the biotechnology sector.

AI News NQ Analysis

[White] Announcement of Board of Directors' Resolution to Appoint Members of the Remuneration Committee

Key facts

[White] Announcement of Board of Directors' Resolution to Appoint Members of the Remuneration Committee
White Biotechnology's Board of Directors has resolved to re-appoint members of the Remuneration Committee upon the expiration of their terms. The new committee includes re-appointed members Lin Shui-Lung, Lai Shan-Kuei, and Wu Yung-Chang, with the addition of Cheng Chien-Hsin. This change is due to the expiration of the committee members' terms.
Source: TWSE
Date: Tue Jun 09 2026 09:00:00 GMT+0900 (Japan Standard Time)

Direct answer

White Biotechnology's Board of Directors has resolved to re-appoint members of the Remuneration Committee upon the expiration of their terms. The new committee includes re-appointed members Lin Shui-Lung, Lai Shan-Kuei, and Wu Yung-Chang, with the addition of Cheng Chien-Hsin. This change is due to the expiration of the committee members' terms.

Citation: [White] Announcement of Board of Directors' Resolution to Appoint Members of the Remuneration Committee (Tue Jun 09 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
Source: TWSE
Date: Tue Jun 09 2026 09:00:00 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

White Biotechnology's Board of Directors has resolved to re-appoint members of the Remuneration Committee upon the expiration of their terms. The new committee includes re-appointed members Lin Shui-Lung, Lai Shan-Kuei, and Wu Yung-Chang, with the addition of Cheng Chien-Hsin. This change is due to the expiration of the committee members' terms.

AI Analysis

Frequently Asked Questions

Q: What is White Biotechnology's Remuneration Committee?: A: The Remuneration Committee is a subcommittee of the Board of Directors responsible for deliberating and deciding on matters related to executive compensation. At White Biotechnology, it is primarily composed of independent directors.
Q: Why are the members of the Remuneration Committee changing?: A: The terms of the committee members have expired, leading the Board of Directors to decide on re-appointments and new appointments. This is a regular procedure within the company's governance framework.
Q: Who is the new member, Cheng Chien-Hsin?: A: Mr. Cheng Chien-Hsin serves as the Director and General Manager of San Fu Biomedical Co., Ltd. He is expected to bring new perspectives and expertise.
Q: Will this personnel change affect the company's performance?: A: A direct impact is currently unclear, but a stable compensation system and proper governance can contribute to long-term corporate value enhancement.
Q: What are White Biotechnology's future business plans?: A: This announcement concerns the members of the Remuneration Committee; specific business development details are pending further disclosure. The company is advancing research and development in the biotechnology sector.